Introduction {#s1}
============

Lipoproteins are lipid-protein complexes whose main function is to transport hydrophobic lipids derived from dietary and endogenous fat to peripheral tissues by the circulation systems for energy utilization or storage. Lipoproteins are primarily formed in and secreted from the intestine, liver, and visceral endoderm ([@bib14]; [@bib52]). Lipoproteins are composed of a neutral lipid core (triglycerides and cholesterol esters) surrounded by a phospholipid monolayer and proteins (called apolipoproteins). At an early stage in lipoprotein assembly, neutral lipids are synthesized and accumulate within the lipid bilayer of the endoplasmic reticulum (ER) membrane ([@bib10]; [@bib54]; [@bib58]; [@bib65]). These lipid structures are associated with apolipoprotein B (APOB), a major protein constituent of lipoproteins, co-and/or post-translationally ([@bib9]). This step requires microsomal triglyceride-transfer protein (MTTP), an ER luminal chaperone that interacts, stabilizes, and lipidates APOB ([@bib52]). Then, lipoproteins are released into the ER lumen ([@bib10]; [@bib54]; [@bib58]; [@bib65]) and transported to the Golgi for secretion. A key long-standing question is how lipoproteins bud off from the ER membrane to the ER lumen, which remains largely unknown.

Vacuole membrane protein 1 (VMP1), which was originally identified as a pancreatitis-associated protein, is a multispanning membrane protein in the ER ([@bib11]; [@bib59]). VMP1 (EPG-3 in *Caenorhabditis elegans*) is essential for autophagosome formation in mammals ([@bib22]; [@bib46]; [@bib57]), *Dictyostelium* ([@bib4]), and *Caenorhabditis elegans* ([@bib57]). Although VMP1 may regulate the PI3K complex I signal ([@bib5]; [@bib26]; [@bib46]), which is required for autophagy ([@bib30]; [@bib33]; [@bib39]; [@bib53]), VMP1 also controls ER contact with other membranes, including autophagic membranes ([@bib56]; [@bib66]), by regulating the calcium pump sarcoendoplasmic reticulum calcium transport ATPase (SERCA) ([@bib66]) and ER contact proteins VAPA and VAPB ([@bib67]). At the ER-autophagic membrane contact sites, VMP1 forms ER subdomains enriched in phosphatidylinositol synthase ([@bib55]), which could serve as the initiation site of autophagosome formation ([@bib40]).

In addition to the involvement in autophagy, VMP1 is known to be required for the secretion of soluble proteins that are transported via the ER-to-Golgi trafficking pathway. In *Drosophila* S2 cells, VMP1 (identified as TANGO5) is important for constitutive secretion and Golgi organization ([@bib1]). In *Dictyostelium*, VMP1 is required for secretion of specific proteins such as α-mannosidase and a cysteine proteinase and maintenance of organelle homeostasis ([@bib4]).

Physiologically, VMP1 is essential for survival under hypoosmotic and starvation conditions in *Dictyostelium* ([@bib4]) and *Caenorhabditis elegans* ([@bib57]), respectively. However, its physiological roles in vertebrates remain unknown. Recent studies in human cells ([@bib38]; [@bib56]; [@bib66]) and *Caenorhabditis elegans* ([@bib66]) revealed that neutral lipid-containing structures accumulate in VMP1-depleted cells, suggesting the function of VMP1 in lipid metabolism. In this study, via deletion of the *VMP1* gene, we found that VMP1 is essential for survival during the larval and early embryonic periods in zebrafish and mice, respectively. We further revealed that VMP1 is important for lipoprotein release from the ER membrane into the lumen to be secreted from the intestine, liver, and visceral endoderm. This function is distinct from previously known functions of VMP1 in autophagy and secretion.

Results {#s2}
=======

Loss of *vmp1* in zebrafish causes larval lethality and defects in autophagy {#s2-1}
----------------------------------------------------------------------------

To reveal the physiological functions of VMP1 in vertebrates, we used zebrafish and mice. We generated *vmp1*-deficient zebrafish using the CRISPR/Cas9 system. A frameshift mutation was introduced into exon 6 of the *vmp1* gene ([Figure 1A](#fig1){ref-type="fig"}). Gross examination revealed that the abdominal part was less transparent in *vmp1^-/-^* zebrafish at 6 days post fertilization (dpf), indicating the presence of abnormal deposits ([Figure 1B](#fig1){ref-type="fig"}). We also noticed that the swimbladder was not inflated in *vmp1^-/-^* zebrafish, which will be described in more detail elsewhere. All *vmp1^-/-^* zebrafish died around at nine dpf ([Figure 1C](#fig1){ref-type="fig"}), suggesting that VMP1 is essential for survival during the larval period.

![Loss of *vmp1* in zebrafish causes lethality around 9 days post fertilization and defective autophagy.\
(**A**) Schematic representation of the Cas9-gRNA-targeted site in the zebrafish *vmp1* genomic locus. The protospacer-adjacent motif (PAM) sequence is shown in red. The targeted site is underlined. A 7 bp deletion in the mutated allele is shown. (**B**) External appearance of 6-dpf *vmp1^+/+^*, *vmp1^+/-^*, and *vmp1^-/-^* zebrafish. Magnified images of the indicated regions are shown in the right panels. Dashed lines indicate abnormal deposits in the liver and intestine. Data are representative of four independent experiments. (**C**) Survival rate (% of total fish) of *vmp1^+/+^* (n = 7), *vmp1^+/-^* (n = 30), and *vmp1^-/-^* (n = 11) zebrafish. Data are representative of two independent experiments. (**D**) Representative images of GFP-LC3 signals in the midbrain, spinal cord, and skeletal muscle of 3-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish injected with GFP-LC3 mRNA. Data are representative of two independent experiments. Scale bars, 10 μm and 1 μm in the inset. (**E**) Immunoblotting of LC3 and β-actin in two 7-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish. Data are representative of two independent experiments.\
10.7554/eLife.48834.003Figure 1---source data 1.Related to [Figure 1C](#fig1){ref-type="fig"}.](elife-48834-fig1){#fig1}

Autophagy was defective in *vmp1^-/-^* zebrafish; many large LC3 puncta accumulated in several tissues, including the brain, spinal cord, and skeletal muscles, which were abnormal autophagy-related structures typically observed in VMP1-deficient mammalian cells ([@bib22]; [@bib29]; [@bib66]) ([Figure 1D](#fig1){ref-type="fig"}). An increase in the levels of the lipidated form of LC3 (LC3-II) was also observed in *vmp1^-/-^* zebrafish ([Figure 1E](#fig1){ref-type="fig"}), as previously observed in VMP1-deficient mammalian cells ([@bib22]; [@bib38]; [@bib51]; [@bib66]). These results suggest that autophagic flux is blocked in *vmp1^-/-^* zebrafish.

Accumulation of neutral lipids in intestinal epithelial cells and hepatocytes in *vmp1*-deficient zebrafish {#s2-2}
-----------------------------------------------------------------------------------------------------------

The abnormal deposits in the abdomen were observed in all *vmp1^-/-^* zebrafish (n = 11), but not in *vmp1^+/-^* (n = 30) or *vmp1^+/+^* zebrafish (n = 7). These deposits resemble neutral lipid accumulation in the intestine ([@bib20]). Indeed, the deposits in *vmp1^-/-^* zebrafish were stained with oil red O, a neutral lipid-soluble dye ([Figure 2A](#fig2){ref-type="fig"}). Oil red O staining of cross sections and electron microscopy revealed that, in *vmp1^-/-^* zebrafish, large neutral lipid-containing structures accumulated in intestinal epithelial cells and hepatocytes ([Figure 2B,C](#fig2){ref-type="fig"}) but not in other organs, including the brain ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}) and skeletal muscles ([Figure 2---figure supplement 1A,C](#fig2s1){ref-type="fig"}). Accumulation of large lipid-containing structures was not observed in zebrafish lacking the *rb1cc1/fip200* ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}) or *atg5* ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}) gene, both of which are required for autophagy ([@bib17]; [@bib32]). These results suggest that neutral lipids accumulate in *vmp1^-/-^* zebrafish, and that this lipid phenotype is not caused by deficient autophagy.

![Loss of *vmp1* in zebrafish causes accumulation of neutral lipids in the intestine and liver.\
(**A**) Whole-mount oil red O staining of 8.5-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish. Data are representative of three independent experiments. (**B**) Oil red O and hematoxylin staining of 6-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish. Data are representative of two independent experiments. Scale bars, 20 μm. (**C**) Transmission electron microscopy of the intestine and liver from 6-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish. Data are representative of three independent experiments. Scale bars, 5 μm.](elife-48834-fig2){#fig2}

Loss of *Vmp1* in mice causes early embryonic lethality and accumulation of lipids in visceral endoderm cells {#s2-3}
-------------------------------------------------------------------------------------------------------------

To elucidate the physiological functions of VMP1 in mammals, *Vmp1*-deficient mice were generated using an embryonic stem (ES) cell line carrying a gene-trap cassette downstream of exon 3 of the *Vmp1* gene ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Heterozygous *Vmp1^gt/+^* mice were healthy and phenotypically indistinguishable from wild-type littermates. In contrast, *Vmp1^gt/gt^* embryos were embryonic lethal; they were detected at 7.5 days postcoitum (dpc) but not after 9.5 dpc ([Figure 3A](#fig3){ref-type="fig"}). *Vmp1^gt/gt^* embryos at 7.5 dpc were smaller than wild-type embryos and accumulated the autophagy substrate p62 ([Figure 3B](#fig3){ref-type="fig"}), suggesting that VMP1 is important for early embryonic development as well as autophagy in mice.

![Systemic and intestinal epithelial cell-specific deletion of *Vmp1* in mice causes accumulation of neutral lipids.\
(**A**) Genotypes of offspring from *Vmp1*^gt/+^ intercross. (**B**) 7.5-dpc embryos were extracted from the conceptus and stained with anti-p62 antibody. Data are representative of two independent experiments. Scale bars, 50 μm. (**C**) 7.5-dpc embryos were stained with LipidTOX Red and Hoechst33342. The visceral endoderm cells are magnified in the insets. Data are representative of two independent experiments. Scale bars, 50 μm and 10 μm in the insets. (**D**) Body weight of *Vmp1^flox/+^*;Villin-*Cre* (n = 4) and *Vmp1^flox/flox^*;Villin-*Cre* (n = 5) male mice at 7--10 months of age. The horizontal lines indicate the means for each group. Differences were determined by unpaired Student *t*-test (\*, p\<0.05). (**E**) The small intestine from 3-month-old *Vmp1^flox/+^*;Villin-*Cre* and *Vmp1^flox/flox^*;Villin-*Cre* mice was stained with anti-p62 antibody and DAPI. Scale bars, 20 μm. (**F**) The small intestine from 8-month-old *Vmp1^flox/+^*;Villin-*Cre* and *Vmp1^flox/flox^*;Villin-*Cre* mice fed *ad libitum* was stained with Nile red and DAPI. Scale bars, 50 μm. (**G**) The amount of serum cholesterol, triglyceride, LDL, and HDL in 18-month-old *Vmp1^flox/+^*;Villin-*Cre* and *Vmp1^flox/flox^*;Villin-*Cre* mice fed *ad libitum*. The horizontal lines indicate the means for each group. Differences were determined by unpaired Student *t*-test (\*, p\<0.05). LDL, low-density lipoprotein; HDL, high-density lipoprotein.\
10.7554/eLife.48834.008Figure 3---source data 1.Related to [Figure 3D,G](#fig3){ref-type="fig"}.](elife-48834-fig3){#fig3}

The visceral endoderm is an extraembryonic layer critical for maternal-to-embryo transfer of nutrients such as neutral lipids between 5 and 10 dpc, before the placenta is formed ([@bib3]). Like intestinal epithelial cells and hepatocytes, visceral endoderm cells secrete lipoproteins to the epiblast, an embryonic layer ([@bib14]). Thus, we examined lipid distribution in these embryos. Indeed, neutral lipids accumulated in visceral endoderm cells in *Vmp1^gt/gt^* embryos at 7.5 dpc ([Figure 3C](#fig3){ref-type="fig"}), as observed in *vmp1*-deficient zebrafish intestinal epithelial cells and hepatocytes.

Intestinal epithelial cell-specific loss of *Vmp1* in mice causes accumulation of lipids in intestinal epithelial cells {#s2-4}
-----------------------------------------------------------------------------------------------------------------------

To circumvent the lethality of *Vmp1^gt/gt^* mouse embryos and study the role of VMP1 in the intestine, we generated intestinal epithelial cell-specific *Vmp1*-deficient mice. Mice harboring a *Vmp1^flox^* allele were crossed with Villin-*Cre* transgenic mice expressing Cre recombinase under the control of the Villin promoter ([@bib12]) ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). *Vmp1^flox/flox^*;Villin-*Cre* mice weighed less than *Vmp1^flox/+^*;Villin-*Cre* mice ([Figure 3D](#fig3){ref-type="fig"}). Accumulation of p62 was observed in intestinal epithelial cells in 3-month-old *Vmp1^flox/flox^*;Villin-*Cre* mice ([Figure 3E](#fig3){ref-type="fig"}). The intestines of 8-month-old *Vmp1^flox/flox^*;Villin-*Cre* mice showed accumulation of neutral lipids within intestinal epithelial cells ([Figure 3F](#fig3){ref-type="fig"}), suggesting a conserved function of VMP1 in the intestine. In the serum from *Vmp1^flox/flox^*;Villin-*Cre* mice, the levels of cholesterol and lipoproteins such as high density lipoprotein (HDL) decreased compared to those from *Vmp1^flox/+^*;Villin-*Cre* mice ([Figure 3G](#fig3){ref-type="fig"}). These results suggest that VMP1 is critical for homeostasis of neutral lipids and lipoproteins in a whole body.

VMP1 is important for secretion of lipoproteins {#s2-5}
-----------------------------------------------

Next, we examined the mechanism by which neutral lipids accumulate in VMP1-depleted organisms. Because intestinal epithelial cells, hepatocytes, and visceral endoderm cells are active in the secretion of lipoproteins ([@bib14]; [@bib52]), we hypothesized that a block in lipoprotein secretion is the cause of lipid accumulation. To this end, we used the human hepatocellular carcinoma cell line HepG2 because these cells constitutively secrete lipoproteins. In *VMP1*-silenced HepG2 cells, the amount of triglyceride and cholesterol decreased in culture media ([Figure 4A,B](#fig4){ref-type="fig"}). In contrast, the intracellular amounts increased ([Figure 4A,B](#fig4){ref-type="fig"}), suggesting that the secretion of neutral lipids depends on VMP1. Chromatographic analysis using different detection methods for neutral lipids also revealed significant reductions in lipoproteins such as very low-density lipoproteins and low-density lipoproteins in the culture media of *VMP1*-silenced HepG2 cells both under normal and oleic acid-treated conditions, the latter of which stimulates lipoprotein secretion ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). Likewise, knockdown of VMP1 reduced the amount of APOB in culture media ([Figure 4C](#fig4){ref-type="fig"}). Paradoxically, it also reduced the amount of intracellular APOB ([Figure 4C](#fig4){ref-type="fig"}). This was likely due to enhanced degradation of misfolded APOB by the ubiquitin-proteasome system because treatment with lactacystin, a proteasome inhibitor, restored the amount of intracellular APOB ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Nevertheless, the amount of extracellular APOB remained lower in *VMP1*-silenced cells than that in control cells ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). These results suggest that VMP1 is critical not only for APOB homeostasis but also for the secretion of lipoproteins.

![VMP1 is important for secretion of lipoproteins.\
(**A and B**) HepG2 cells were treated with siRNA against *luciferase* (*Luc*) or *VMP1* and cultured in serum-free medium for 24 hr. Triglycerides (**A**) and cholesterols (**B**) were extracted from culture medium and cells, measured and analyzed using the Student's *t*-test (\*\*, p\<0.01; \*, p\<0.05). The horizontal lines indicate the means of three independent experiments for each group. (**C**) HepG2 cells were treated as in (**A**) and cultured in regular medium containing 200 nM oleic acid for 24 hr. Cells were then washed and re-cultured in serum-free medium for indicated times. The medium was concentrated by TCA precipitation. Samples (approximately 7% or 14% vol of total precipitated media or cell lysates, respectively) were subjected to immunoblot analysis. The amount of proteins was quantified through densitometric scanning of band intensities and the medium/cells ratio was determined. Data represent the mean ± standard error of the mean (n = 3), which was normalized to 0 hr, and statistically analyzed using the Student's *t*-test (\*\*, p\<0.01; \*, p\<0.05).\
10.7554/eLife.48834.012Figure 4---source data 1.Related to [Figure 4A--C](#fig4){ref-type="fig"}.](elife-48834-fig4){#fig4}

We next investigated whether VMP1 is required for secretion of proteins besides APOB. Secretion of APOE, a component of very low density lipoprotein (VLDL), and APOA-I, a component of HDL, was also impaired in *VMP1*-silenced HepG2 cells ([Figure 4C](#fig4){ref-type="fig"}). Secretion of APOA-I was affected only slightly. In contrast, secretion of albumin, which is transported from the ER to Golgi separately from lipoproteins ([@bib58]), was not significantly impaired in *VMP1*-silenced HepG2 cells ([Figure 4C](#fig4){ref-type="fig"}). Secretion of collagens, another type of large cargo that requires TANGO1 for secretion ([@bib48]), was not affected by VMP1 deletion because cartilage structures, which are composed of collagens secreted from cartilage cells, was normal in *vmp1^-/-^* zebrafish ([Figure 4---figure supplement 1D,E](#fig4s1){ref-type="fig"}). This result is consistent with a previous report that showed the secretion of collagens and model cargo proteins such as VSVG, a glycoprotein of vesicular stomatitis virus, is normal in *vmp1/epg-3* mutant *Caenorhabditis elegans* and *VMP1* knockout COS7 cells, respectively ([@bib66]). Thus, a defect in secretion in VMP1-deficient cells is not general, but rather specific to lipoproteins.

Neutral lipids accumulate in the ER in the absence of VMP1 {#s2-6}
----------------------------------------------------------

In intestinal epithelial cells and hepatocytes, neutral lipids are synthesized within the lipid bilayer of the ER membrane and released into the ER lumen for secretion ([@bib10]; [@bib54]; [@bib58]; [@bib65]). In *vmp1^-/-^* zebrafish, almost all large lipid-containing structures in intestinal epithelial cells and hepatocytes were surrounded by the ER transmembrane protein Sec61B ([Figure 5A](#fig5){ref-type="fig"}). In most cases, Sec61B covered only a part rather than all of the surface of the lipid structures. Also, in *Vmp1^gt/gt^* mouse embryos, almost all neutral lipid-containing structures were positive for SEC61B ([Figure 5B](#fig5){ref-type="fig"}). In contrast, neutral lipid structures in these tissues in *vmp1^+/-^* animals were mostly negative for Sec61B/SEC61B, suggesting that they are present outside the ER, most likely as cytosolic lipid droplets ([Figure 5A,B](#fig5){ref-type="fig"}). Thus, neutral lipids abnormally accumulate in the ER in *vmp1*-deficient zebrafish and mouse tissues.

![*Vmp1*-deficient zebrafish and mice show accumulation of lipoproteins in the intestine, liver, and visceral endoderm.\
Immunohistochemistry of the intestine and liver from 6-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish (**A and C**) and the visceral endoderm from 7.5-dpc *Vmp1^gt/+^* and *Vmp1^gt/gt^* mice (**B and D**) using anti-SEC61B antibody (**A and B**), anti-APOB antibody (**C and D**), LipidTOX Red, and Hoechst33342. Arrows indicate the regions where the Sec61B/SEC61B signals were weak. The regions of zebrafish intestinal epithelial cells (**E**), intestinal lumen (**L**) or mouse visceral endoderm cells (VE) are shown as dashed lines. Data are representative of two independent experiments. Scale bars, 10 μm and 1 μm in the inset. The number of LipidTOX Red (+) structures with (black columns) or without (white columns) SEC61B (**A and B**) or APOB (**C and D**) per observed area was analyzed from at least two randomly selected areas using ImageJ software.\
10.7554/eLife.48834.014Figure 5---source data 1.Related to [Figure 5A--D](#fig5){ref-type="fig"}.](elife-48834-fig5){#fig5}

VMP1 is important for the release of lipoproteins from the ER membrane {#s2-7}
----------------------------------------------------------------------

We further narrowed down the step defective in VMP1-deficient cells. Neutral lipids accumulating within lipid bilayers of the ER are released into the ER lumen to form lipoproteins together with APOB ([@bib52]). In *vmp1^-/-^* zebrafish, most of the lipid-containing structures were positive for ApoB ([Figure 5C](#fig5){ref-type="fig"}). In addition, the lipid structures were mostly positive for APOB in *Vmp1^gt/gt^* mouse embryos ([Figure 5D](#fig5){ref-type="fig"}). In agreement with SEC61B staining data, most lipid structures in these tissues in *vmp1^+/-^* animals were ApoB/APOB-negative ([Figure 5C,D](#fig5){ref-type="fig"}). These results suggest that lipoproteins or lipoprotein-related structures are formed and accumulate in VMP1-deficient cells.

In wild-type HepG2 cells, neutral lipid structures were mostly positive for adipose differentiation-related protein (ADRP, also known as perilipin 2), a marker for cytosolic lipid droplets, but negative for APOB irrespective of oleic acid treatment that increased the number of lipid-containing structures ([Figure 6A--C](#fig6){ref-type="fig"}), suggesting that these are lipid droplets rather than lipoproteins. In contrast, as shown in zebrafish and mice ([Figure 5](#fig5){ref-type="fig"}), large lipid structures accumulated in *VMP1*-silenced HepG2 cells ([Figure 6A](#fig6){ref-type="fig"}) and most of them were APOB positive ([Figure 6C](#fig6){ref-type="fig"}). Some of them were positive for both APOB and ADRP, where APOB and ADRP were distributed into distinct regions ([Figure 6D](#fig6){ref-type="fig"}). They should represent structures stuck within the ER lipid bilayers facing both the cytosol and the ER lumen, rather than those released into the ER lumen ([Figure 6D](#fig6){ref-type="fig"}). APOE, but not APOA-I, colocalized with APOB on the lipid structures in *VMP1*-silenced HepG2 cells ([Figure 6E,F](#fig6){ref-type="fig"}), suggesting that the defective secretion of APOB and APOE ([Figure 4C](#fig4){ref-type="fig"}) is at least partly caused by trapping in the lipid structures.

![Depletion of VMP1 in HepG2 cells causes accumulation of abnormal lipoproteins.\
(**A--C**) HepG2 cells were treated with siRNA oligonucleotides against *luciferase* (*Luc*) or *VMP1*, cultured in regular medium in the presence or absence of 200 nM oleic acid for 24 hr, and stained with BODIPY-C~12~ 558/568 for 1 hr to visualize the neutral lipids. Cells were fixed and stained with anti-APOB and anti-ADRP antibodies. Scale bars, 10 μm and 2 μm in the inset. The number of neutral lipid particles per cell (**B**) and ratio of APOB- or ADRP-positive neutral lipid particles (**C**) was quantified. Solid bars indicate median, boxes the interquartile range (25th to 75th percentile), and whiskers 1.5 times the interquartile range. The outliers are plotted individually. Differences were determined by Mann-Whitney U-test (\*\*, p\<0.01; \*, p\<0.05; n ≥ 17 cells). (**D**) Representative images of APOB- and ADRP-double positive neutral lipid particles in VMP1-depleted HepG2 cells. Scale bars, 2 μm. A model of APOB- and ADRP-double positive neutral lipid particles in VMP1-depleted cells is shown. (**E and F**) HepG2 cells were treated as in (**A**), cultured in regular medium, and stained with BODIPY-C~12~ 558/568 for 1 hr. Cells were fixed and stained with indicated antibodies. Scale bars,10 μm and 2 μm in the inset.\
10.7554/eLife.48834.020Figure 6---source data 1.Related to [Figure 6B,C](#fig6){ref-type="fig"}.](elife-48834-fig6){#fig6}

Similar crescent-shaped accumulations of APOB and ADRP around lipids trapped within the ER membranes were also observed in human hepatoma cell line Huh7 cells treated with proteasome inhibitors ([@bib41]). In *VMP1*-silenced HepG2 cells, however, proteasome activity was not suppressed ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). In addition, treatment of wild-type HepG2 cells with proteasome inhibitors (MG132 or lactacystin) did not induce crescent-shaped accumulations of APOB and ADRP ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). These results are somehow different from those in the previous report ([@bib41]), probably because of a difference in cell types or culture conditions. The crescent-shaped accumulations of APOB and ADRP was also observed by treatment with docosahexaenoic acid or cyclosporin A ([@bib41]), which induce APOB proteolysis by unknown molecular mechanisms ([@bib15]; [@bib27]), suggesting the possible involvement of APOB proteolysis in the formation of these structures. APOB was degraded by induction of ER stress or depletion of MTTP ([@bib43]; [@bib52]). However, neither ER stress ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}) or reduced MTTP protein level ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}) was observed in *VMP1*-silenced HepG2 cells. Treatment of wild-type HepG2 cells with ER stress inducers (tunicamycin or thapsigargin) ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}) or an MTTP inhibitor (CP-346086) ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}) did not induce the crescent-shaped accumulations of APOB and ADRP. Furthermore, the crescent-shaped accumulations of APOB and ADRP were not observed in HepG2 cells deficient for FITM2 ([Figure 6---figure supplement 2D,E](#fig6s2){ref-type="fig"}), a factor required for budding of lipid droplets from the ER membrane to the cytosol, but not for lipoprotein secretion ([@bib6]; [@bib16]; [@bib24]). Taken together, these results suggest that the crescent-shaped accumulations of APOB and ADRP in *VMP1*-silenced HepG2 cells is not due to proteasome inhibition, ER stress, MTTP suppression, or defective budding of lipid droplets from the ER membrane.

Electron microscopy of intestinal epithelial cells ([Figure 7A](#fig7){ref-type="fig"}) and hepatocytes ([Figure 7B](#fig7){ref-type="fig"}) of *vmp1^-/-^* zebrafish and *VMP1*-silenced HepG2 cells ([Figure 7C](#fig7){ref-type="fig"}) revealed that the ER membranes with ribosomes on their cytosolic face covered a part of the surface of the lipid structures ([Figure 7A--C](#fig7){ref-type="fig"}, black arrowheads) and fused with the lipid structures at both ends ([Figure 7A--C](#fig7){ref-type="fig"}, white arrowheads). The space between the ER membrane and the lipid structures should be the ER lumen ([Figure 7D](#fig7){ref-type="fig"}). In contrast, lipid accumulation within the ER membrane was not observed in *vmp1^+/-^* zebrafish and wild-type HepG2 cells ([Figure 7A--C](#fig7){ref-type="fig"}, arrows). In hepatocytes in *vmp1^+/-^* zebrafish, there was no membrane on large lipid structures, which should represent cytosolic lipid droplets ([Figure 7B](#fig7){ref-type="fig"}). These results suggest that neutral lipids abnormally accumulate within the lipid bilayer of the ER membrane in the absence of VMP1, and VMP1 is important for the release of lipoproteins into the ER lumen ([Figure 7D](#fig7){ref-type="fig"}).

![Neutral lipids accumulate within the ER membrane in the absence of VMP1.\
(**A--C**) Transmission electron microscopy of intestinal epithelial cells (**A**) and hepatocytes (**B**) from 6-dpf *vmp1^+/-^* and *vmp1^-/-^* zebrafish and VMP1-depleted HepG2 cells (**C**). Black and white arrowheads indicate the presence and absence of a lipid bilayer on neutral lipid-containing structures, respectively. Arrows indicate the ER membrane. Data are representative of three independent experiments. Scale bars, 500 nm and 100 nm in magnified panels. (**D**) Models for the membrane structure on lipids in the ER in wild-type and VMP1-deficient cells. Black and white arrowheads correspond to those in (**A**) to (**C**). In VMP1-deficient cells, the surfaces of neutral lipid structures (monolayer) are continuous to the ER membranes (bilayer), whereas only phospholipid monolayers cover neutral lipid structures in normal cells.](elife-48834-fig7){#fig7}

Discussion {#s3}
==========

Based on the findings in this study, we propose that the ER protein VMP1 has a novel nonautophagic function in the release of lipoproteins from the ER membrane into the lumen ([Figure 7D](#fig7){ref-type="fig"}). This step is distinct from the exit from the ER; it is generally thought that intraluminal lipoproteins are transported to the Golgi ([Figure 7D](#fig7){ref-type="fig"}). Consistently, the phenotype of deletion of VMP1 is different from that of factors required for lipoprotein export from the ER lumen to the Golgi ([Figure 7D](#fig7){ref-type="fig"}); deletion of TANGO1, TALI ([@bib49]), cTAGE5 ([@bib62]), or SURF4 ([@bib47]) does not cause an accumulation of large lipid-containing structures in human hepatocellular carcinoma cells or epithelial colorectal adenocarcinoma cells. However, as it is technically difficult to definitely demonstrate where each apolipoprotein and neutral lipids accumulate in the ER, we do not exclude the possibility that VMP1 is also important at the step of ER-to-Golgi budding, which is not mutually exclusive.

Our results also suggest that VMP1 is important for the release of lipid droplets from the ER membrane to the cytosol because the number of ADRP-positive lipid droplets decreased in *VMP1*-silenced HepG2 cells ([Figure 6A,C](#fig6){ref-type="fig"}). Thus, VMP1 may regulate a common process shared by the three pathways derived from the ER: autophagy, lipoprotein formation, and lipid droplet formation. One hypothesis is that VMP1 might regulate remodeling of the ER membrane. The release of neural lipid-containing structures from the ER membrane to the ER lumen or the cytosol would require drastic reorganization of the membrane ([Figure 7D](#fig7){ref-type="fig"}). In addition, during autophagy, the ER membranes dramatically change their shapes and contact with the autophagic membranes ([@bib18]; [@bib66]; [@bib67]). Without VMP1, expansion of the autophagic membranes is defective ([@bib29]; [@bib38]). In *Drosophila* S2 cells ([@bib1]) and in *Dictyostelium* ([@bib4]), but not in *Caenorhabditis elegans* or in mammalian cells ([@bib66]), VMP1 was reported to be important for the secretion of some soluble cargos. Therefore, in some organisms, VMP1 may also be involved in the budding process of the ER membrane toward the Golgi, and this is achieved possibly by regulating the shape of the ER membrane. Since the release of lipoproteins and lipid droplets from the ER membrane can be regulated by lipid metabolism such as phospholipid remodeling ([@bib2]; [@bib63]), VMP1 could play a possible role in lipid metabolism. Further investigations, in particular, structural analyses of VMP1 and its functionally related protein TMEM41B ([@bib36]; [@bib38]; [@bib51]), as well as lipidomic analysis of cells lacking these factors, will reveal their molecular functions in the ER membrane.

In this study, we showed that VMP1 is essential for survival during larval periods and early embryonic periods in zebrafish and mice, respectively. *Vmp1*-deficient mice died around at 8.5 dpc. This timing of lethality is earlier than that of mice deficient for other core autophagy-related genes such as *Rb1cc1*, *Atg13*, and *Atg5* ([@bib31]; [@bib34]). Considering the early embryonic lethality of *ApoB*- or *Mttp*-deficient mice around at 10.5 dpc due to malabsorption of lipids from maternal blood ([@bib13]; [@bib14]; [@bib45]), one of the causes of the early embryonic lethality of *Vmp1*-deficient mice is likely the same mechanism. The reduction of body weight ([Figure 3D](#fig3){ref-type="fig"}) and levels of serum cholesterol and lipoproteins ([Figure 3G](#fig3){ref-type="fig"}) in intestinal epithelial cell-specific *Vmp1*-deficient mice indicates defects in the absorption of nutrients. In contrast to intestinal epithelial cell-specific *Mttp*-deficient mice ([@bib21]; [@bib64]), intestinal epithelial cell-specific *Vmp1*-deficient mice showed milder phenotypes in lipoprotein secretion; the level of serum triglyceride did not decrease in intestinal epithelial cell-specific *Vmp1*-deficient mice ([Figure 3G](#fig3){ref-type="fig"}). Thus, although VMP1 is important, it is not absolutely essential for lipoprotein secretion.

Two independent genome-wide association studies in humans identified intronic single-nucleotide polymorphism associations (rs11650106 and rs2645492) in the *VMP1* gene with altered levels of circulating LDL ([@bib7]; [@bib19]). Thus, VMP1 may be important for the regulation of the levels of circulating lipoproteins in humans. Further examination of the function of VMP1 in a whole organism would provide new insights into the regulation of lipid homeostasis under physiological as well as disease conditions.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                             Source or reference                                              Identifiers                                                                           Additional\
  (species) or resource\                                                                                                                                                                                                           information
  \                                                                                                                                                                                                                                
  --------------------------------- --------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------- -------------------------
  Genetic reagent (*D. rerio*)      *vmp1*                                  this paper                                                                                                                                             

  Genetic reagent (*D. rerio*)      *rb1cc1/fip200*                         PMID: [27818143](https://www.ncbi.nlm.nih.gov/pubmed/27818143)                                                                                         

  Genetic reagent (*D. rerio*)      *atg5*                                  this paper                                                                                                                                             

  Genetic reagent (*M. musculus*)   *Vmp1^-/-^*                             KOMP Repository                                                  MGI allele Vmp1tm1a(KOMP)Wtsi, clone EPD0846_3\_F07                                   

  Genetic reagent (*M. musculus*)   *Vmp1^flox/flox^*                       The European Mouse Mutant Archive                                EMMA ID: EM05506                                                                      

  Genetic reagent (*M. musculus*)   Villin-*Cre*                            Model Animal Research Center of Nanjing University                                                                                                     

  Cell line (*H. sapiens*)          HepG2                                   ATCC                                                             Cat. \# HB-8065\                                                                      Negative for mycoplasma
                                                                                                                                             RRID: [CVCL_0027](https://scicrunch.org/resolver/CVCL_0027)                           

  Antibody                          anti-ADRP (rabbit polyclonal)           Proteintech                                                      Cat. \#15294--1-AP                                                                    IF (1:200)

  Antibody                          anti-albumin (rabbit polyclonal)        Proteintech                                                      Cat. \#16475--1-AP, RRID: [AB_2242567](https://scicrunch.org/resolver/AB_2242567)     WB (1:1000)

  Antibody                          anti-APOA-I (mouse monoclonal)          Proteintech                                                      Cat. \#66206--1-Ig                                                                    WB (1:1000)

  Antibody                          anti-APOA-I (rabbit polyclonal)         Abcam                                                            Cat. \#ab64308                                                                        IF (1:200)

  Antibody                          anti-APOB (goat polyclonal)             Rockland Immunochemicals Inc                                     Cat. \#600-101-111, RRID: [AB_2056958](https://scicrunch.org/resolver/AB_2056958)     WB (1:1000)\
                                                                                                                                                                                                                                   IF (1:200)

  Antibody                          anti-APOB (rabbit polyclonal)           Abcam                                                            Cat. \#ab20737, RRID: [AB_2056954](https://scicrunch.org/resolver/AB_2056954)         IHC (1:200)

  Antibody                          anti-APOE (mouse monoclonal)            Proteintech                                                      Cat. \#66830--1-Ig                                                                    WB (1:1000)\
                                                                                                                                                                                                                                   IF (1:200)

  Antibody                          anti-α-tubulin (mouse monoclonal)       Sigma-Aldrich                                                    Cat. \#T9026, RRID: [AB_477593](https://scicrunch.org/resolver/AB_477593)             WB (1:1000)

  Antibody                          anti-β-actin (mouse monoclonal)         Sigma-Aldrich                                                    Cat. \#A2228, RRID: [AB_476697](https://scicrunch.org/resolver/AB_476697)             WB (1:1000)

  Antibody                          anti-BiP (rabbit polyclonal)            Abcam                                                            Cat. \#ab21685, RRID: [AB_2119834](https://scicrunch.org/resolver/AB_2119834)         WB (1:1000)

  Antibody                          anti-HERP (mouse monoclonal)            Chondrex                                                         Cat. \#7039                                                                           WB (1:1000)

  Antibody                          anti-LC3 (mouse monoclonal)             Cosmo Bio                                                        Cat. \#CTB-LC3-2-IC                                                                   WB (1:1000)

  Antibody                          anti-LDH (rabbit monoclonal)            Abcam                                                            Cat. \#ab52488, RRID: [AB_2134961](https://scicrunch.org/resolver/AB_2134961)         WB (1:1000)

  Antibody                          anti-MTTP (mouse monoclonal)            Santa Cruz                                                       Cat. \#sc-135994, RRID: [AB_2148288](https://scicrunch.org/resolver/AB_2148288)       WB (1:1000)

  Antibody                          anti-p62 (rabbit polyclonal)            MBL International                                                Cat. \#PM045, RRID: [AB_1279301](https://scicrunch.org/resolver/AB_1279301)           IHC (1:200)

  Antibody                          anti-PDI (mouse monoclonal)             Enzo Life Sciences                                               Cat. \#ADI-SPA-891, RRID: [AB_10615355](https://scicrunch.org/resolver/AB_10615355)   WB (1:1000)

  Antibody                          anti-SEC61B (rabbit polyclonal)         Proteintech                                                      Cat. \#15087--1-AP, RRID: [AB_2186411](https://scicrunch.org/resolver/AB_2186411)     IHC (1:200)

  Antibody                          anti-VMP1 (rabbit polyclonal)           MBL International                                                Cat. \#PM072                                                                          WB (1:1000)

  commercial assay or kit           Cholesterol Quantitation Kit            Biovision inc                                                    Cat. \#K603-100                                                                       

  commercial assay or kit           Cell-Based Proteasome-Glo Assays        Promega                                                          Cat. \#G8660                                                                          

  commercial assay or kit           Triglyceride Quantification Kit         Biovision inc                                                    Cat. \#K622-100                                                                       

  chemical compound, drug           BSA-conjugated oleic acid               Nacalai Tesque                                                   Cat. \#25630                                                                          

  chemical compound, drug           CP-346086                               Sigma-Aldrich                                                    Cat. \#PZ0103                                                                         

  chemical compound, drug           Lactacystin                             Peptide Institute Inc                                            Cat. \#4368-v                                                                         

  chemical compound, drug           MG132                                   Sigma-Aldrich                                                    Cat. \#M8699                                                                          

  chemical compound, drug           Thapsigargin                            Sigma-Aldrich                                                    Cat. \#586005                                                                         

  chemical compound, drug           Tunicamycin                             Sigma-Aldrich                                                    Cat. \#T7765                                                                          

  Other                             BODIPY 558/568 C~12~                    Thermo Fisher Scientific                                         Cat. \#D3835                                                                          

  Other                             4\',6-diamidino-2-phenylindole (DAPI)   Sigma-Aldrich                                                    Cat. \#D9542                                                                          

  Other                             Hoechst33342                            Dojindo Molecular Technologies                                   Cat. \#H342                                                                           

  Other                             LipidTOX Red                            Thermo Fisher Scientific                                         Cat. \#H34476                                                                         

  Other                             Nile red                                Thermo Fisher Scientific                                         Cat. \#N1142                                                                          

  Other                             Oil red O                               Sigma-Aldrich                                                    Cat. \#O0625                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Zebrafish {#s4-1}
---------

RIKEN Wako wild-type strain was obtained from the Zebrafish National Bioresource Project of Japan, raised, and maintained in 14 hr light/10 hr dark conditions at 28.5°C according to established protocols ([@bib28]). *Vmp1^-/-^* zebrafish were generated using the CRISPR/Cas9 system ([@bib23]) including pT7-gRNA, a gift from Wenbiao Chen (plasmid \#46759, Addgene), and Cas9 mRNA (CAS500A-1, System Biosciences). A region within exon 6 of zebrafish *vmp1* gene was targeted based on CRISPRscan ([@bib35]) (target sequence was 5'-ccaTTGGTGAGCTGCCTCCATAC-3', where the protospacer adjacent motif is indicated by lower cases). gRNA was synthesized using a MEGAshortscript T7 transcription kit (AM1354, Thermo Fisher Scientific) and purified using a mirVana miRNA Isolation Kit (AM1560, Thermo Fisher Scientific). Wild-type embryos were microinjected at the one-cell stage with 100 pg of sgRNA and 300 pg of Cas9 mRNA using FemtoJet (Eppendorf) equipped with a Femtotip II injection capillary (Eppendorf). For genotyping of *vmp1^-/-^* zebrafish, heteroduplex mobility assay ([@bib44]) was performed using genomic DNA, primers flanking the target site (forward primer, 5\'-GCTCATCATTTGTACATGCGTGCGTG-3\'; reverse primer, 5'-GCTCCAGCATCTCCTCGAATTCTTC-3'), PrimeSTAR Max DNA polymerase (R045A, TaKaRa Bio Inc), and 10% polyacrylamide gels. *Vmp1^-/-^* zebrafish were generated by intercrossing *vmp1^+/-^* zebrafish harboring a 7 bp deletion. *Rb1cc1^-/-^* and *atg5^-/-^* zebrafish were generated using *rb1cc1^+/-^* zebrafish harboring a 13 bp deletion in exon 4 and *atg5^+/-^* zebrafish harboring a 4 bp insertion in exon 3, respectively. Detailed descriptions of the phenotypes of the *rb1cc1^-/-^* and *atg5^-/-^* zebrafish will be reported elsewhere. Defects in autophagy in *rb1cc1^-/-^* zebrafish have been previously confirmed ([@bib25]).

A survival assay of zebrafish larvae was performed on progeny from intercrosses of *vmp1^+/-^* zebrafish in the same nursery environment without food. Dead larvae were collected twice a day and frozen. At 13 dpf, the remaining larvae were sacrificed, and all larvae including dead zebrafish were genotyped. Results are shown as Kaplan-Meier survival curves. The external appearance of zebrafish larvae was observed and imaged by a stereoscopic microscope (SZX10, Olympus).

Mice {#s4-2}
----

The *Vmp1^gt/gt^* mouse line was generated using the ES cell line Vmp1_F07 (CSD80081) containing an insertion of a gene trap (*gt*) cassette in the *Vmp1* gene (purchased from the Knockout Mouse Project Repository). ES cells were injected into C57BL/6 blastocysts to obtain chimeric mice, which were crossed with C57BL/6 mice to obtain heterozygous mutant mice. For genotyping of *Vmp1^gt/gt^* mice, genomic DNA was isolated from the tail or epiblasts dissected from the conceptus and amplified by PCR using primers (F1, 5\'-CCCAAGTCTGCTTTACTGACAGCC-3\'; F2, 5\'-GGGATCTCATGCTGGAGTTCTTCG-3\'; R, 5\'-TTACTCAGACAGCCTTTCTCCACCC-3\') to detect both 445 bp and 640 bp products for wild-type and *gt* alleles, respectively. The external appearance of mouse embryos was observed and imaged by a stereoscopic microscope (SZX10, Olympus). Wild-type C57BL/6 mice were obtained from Japan SLC, Inc.

The *Vmp1^flox^* mice were purchased from The European Mouse Mutant Archive (EM:05506). The exons 3 and 4 of *Vmp1* were flanked by two *loxP* sequences. Cre-mediated depletion of exons 3 and 4 leads to a frameshift, resulting in a small truncated peptide. The following primers were used to detect wild-type and floxed alleles of *Vmp1*: 5'-GCTTGCTGTGAATGGTTACC-3' (forward) and 5'-TCAGATCAGCCTTCTGTAGG-3' (reverse). The expected sizes are 266 bp and 391 bp, respectively. To generate intestinal epithelial cell-specific *Vmp1* knockout mice, *Vmp1^flox/flox^* mice were crossed with Villin-*Cre* mice (Model Animal Research Center of Nanjing University). Mice were maintained under specific pathogen-free conditions in the animal facility at the Institute of Biophysics, Chinese Academy of Sciences, Beijing.

All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Tokyo (Medical-P17-084) and the Institutional Committee of the Institute of Biophysics, Chinese Academy of Sciences (SYXK2016-35).

Cell culture {#s4-3}
------------

HepG2 cells (HB-8065, ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM; D6546, Sigma-Aldrich) supplemented with 10% fetal bovine serum (172012, Sigma-Aldrich) and 2 mM L-glutamine (25030--081, Gibco; regular medium) in a 5% CO~2~ incubator. HepG2 cells were regularly tested and found to be mycoplasma-free by DAPI DNA staining. For neutral lipid staining, cells were cultured with regular medium containing 10% serum and 1 μg/mL BODIPY 558/568 C~12~ (D3835, Thermo Fisher Scientific) for 1 hr.

RNA interference {#s4-4}
----------------

Stealth RNAi oligonucleotide (Thermo Fisher Scientific) against human *VMP1* or *FITM2* was used for small interfering RNA (siRNA) experiments. The following sequences were used: human *VMP1* siRNA 5\'-GCAUCAACAGUAUGUGCAACGUAUA-3\' and human *FITM2* siRNA 5\'- AAACAAGGUGCCAAACACCUUCUGG-3\'. For the negative control, siRNA against *luciferase* (5\'-CGCGGUCGGUAAAGUUGUUCCAUUU-3\') (Thermo Fisher Scientific) was used. The Stealth RNAi oligonucleotides were transfected into cells using Lipofectamine RNAiMAX (13778--150, Thermo Fisher Scientific) according to the manufacturer's protocols. After 2 days, the cells were again transfected with the same siRNA and cultured for an additional 3 days before analysis.

Antibodies and reagents {#s4-5}
-----------------------

For immunoblotting, goat polyclonal anti-APOB (600-101-111, Rockland Immunochemicals Inc), rabbit polyclonal anti-VMP1 (PM072, MBL International), anti-Albumin (16475--1-AP, Proteintech), anti-BiP (ab21685, Abcam), mouse monoclonal anti-LC3 (CTB-LC3-2-IC, Cosmo Bio), anti-α-tubulin (T9026, clone DM1A, Sigma-Aldrich), anti-β-actin (A2228, clone AC-74, Sigma-Aldrich), anti-APOA-I (66206--1-Ig, clone 1C9G5, Proteintech), anti-APOE (66830--1-Ig, clone 1B2c9, Proteintech), anti-HERP (7039, clone HT2, Chondrex), anti-MTTP (sc-135994, Santa-Cruz), anti-PDI (ADI-SPA-891, clone 1D3, Enzo Life Sciences), and rabbit monoclonal anti-lactate dehydrogenase (LDH; ab52488, Abcam) antibodies were used as primary antibodies. Anti-goat (305-035-003), anti-mouse (115-035-003), and anti-rabbit (111-035-144) horseradish peroxidase-conjugated immunoglobulin G (IgG; Jackson ImmunoResearch Laboratories) were used as secondary antibodies. For immunostaining, goat polyclonal anti-APOB antibody and rabbit polyclonal anti-APOE, anti-ADRP/perilipin2 (15294--1-AP, Proteintech), and anti-APOA-I (ab64308, Abcam) antibodies were used as primary antibodies for the staining of culture cells. Rabbit polyclonal anti-APOB (ab20737, Abcam), anti-SEC61B (15087--1-AP, Proteintech), and anti-p62 (PM045, MBL International) antibodies were used for the staining of tissues. AlexaFluor 488-conjugated anti-goat IgG (A11055, Thermo Fisher Scientific), AlexaFluor 488-conjugated anti-rabbit IgG (A11008, Thermo Fisher Scientific), AlexaFluor 647-conjugated anti-rabbit IgG (A31573, Thermo Fisher Scientific), and AlexaFluor 647-conjugated anti-mouse IgG (A31571, Thermo Fisher Scientific) were used as secondary antibodies. For staining of the mouse intestine, FITC-conjugated anti-rabbit IgG (111-095-003, Jackson ImmunoResearch Laboratories) was used. Hoechst33342 (H342, Dojindo Molecular Technologies) and 4′,6-diamidino-2-phenylindole (DAPI; D9542, Sigma-Aldrich) was used to stain DNA. LipidTOX Red (H34476, Thermo Fisher Scientific) was used to stain neutral lipids. Bovine serum albumin (BSA)-conjugated oleic acid (25630, Nacalai Tesque) was prepared as previously reported ([@bib60]). Lactacystin (4368 v) was purchased from the Peptide Institute Inc. MG132 (M8699), tunicamycin (T7765), thapsigargin (586005) and CP-346086 (PZ0103) were purchased from Sigma-Aldrich.

Live imaging of zebrafish embryos {#s4-6}
---------------------------------

Zebrafish eggs at the one-cell stage were microinjected with 50 ng/µL of GFP-LC3 mRNA, which was synthesized from pcDNA3-GFP-LC3-RFP-LC3ΔG plasmid ([@bib25]) using a mMESSAGE mMACHINE T7 Transcription Kit (AM1344, Thermo Fisher Scientific) and purified using RNeasy Mini Kit (74104, Qiagen). Embryos were anesthetized with 0.03% tricaine (A5040, Sigma-Aldrich), placed in water on a glass-bottomed dish, and viewed using a confocal microscope (FV1000 IX81; Olympus) with an objective lens (UPLSAPO30XS, Olympus).

Immunohistochemistry {#s4-7}
--------------------

Immunohistochemistry of tissues was performed as described previously ([@bib37]). In brief, zebrafish larvae and mouse embryos dissected from the conceptus were fixed in 4% paraformaldehyde (PFA) overnight at 4°C, infiltrated with 15% and 30% sucrose in phosphate-buffered saline (PBS) for 4 hr each, and embedded in Tissue-Tek OCT Compound (Sakura Japan Co.). Sections (7 μm) were prepared using a cryostat (CM3050 S, Leica Microsystems) and mounted on slides. For whole-mount staining of mouse embryos, embryos were dissected from the conceptus and fixed with 4% PFA for 15 min at 4°C. Cryosections or mouse embryos were washed with PBS, treated with 0.05% Triton X-100 for 15 min, blocked with 3% BSA in PBS for 30 min, and incubated with primary antibodies for 1 hr, followed by PBS wash and incubation with secondary antibodies for 1 hr. For staining of neutral lipids and nuclear DNA, samples were treated with LipidTOX Red and Hoechst33342 in PBS for 30 min and washed three times with PBS. The coverslips and mouse embryos in a glass-bottomed dish were mounted with SlowFade antifade reagents (S36936, Thermo Fisher Scientific), viewed using a confocal laser microscope (FV1000 IX81, Olympus), and captured with FluoView software (Olympus). The number of punctate structures was determined using FIJI software (ImageJ, National Institutes of Health) ([@bib50]).

For p62 and DAPI staining in intestinal epithelial cell-specific *Vmp1*-deficient mice, sections were deparaffinized in xylene and rehydrated in an ethanol series (100% × 3, 95%, and 75%). Antigen retrieval was performed using microwaves (0.01 M citrate buffer for 10 min). After blocking, sections were incubated with primary antibodies at 4°C overnight. After washing three times in PBS, sections were incubated with fluorescent-labeled secondary antibodies for 1 hr at room temperature. Samples were then counterstained with DAPI and detected under a confocal microscope (LSM 880 Meta plus Zeiss Axiovert zoom, Zeiss).

Oil red O and Nile red staining {#s4-8}
-------------------------------

Whole-mount oil red O staining was performed according to a previous method ([@bib8]). In brief, zebrafish larvae were maintained in 0.2 mM 1-phenyl-2-thiourea (PTU) to avoid pigmentation from one dpf, fixed with 4% PFA overnight at 4°C, washed twice with PBS, infiltrated with 80% and 100% 1,2-propylene glycol for 30 min each, and stained with 0.5% oil red O (O0625, Sigma-Aldrich) in 100% 1,2-propylene glycol overnight at room temperature. Stained larvae were washed twice with PBS and the background color was faded with 100% and 80% 1,2-propylene glycol for 30 min each, and observed by a stereoscopic microscope (SZX10, Olympus). For oil red O staining of cryosections, zebrafish larvae were fixed in 4% PFA overnight at 4°C, infiltrated with 15% and 30% sucrose for 4 hr each at 4°C, and embedded in Tissue-Tek OCT Compound. Sections (6 μm) were mounted on slides and stained with oil red O in 60% isopropanol for 15 min at 37°C, followed by a 60% isopropanol wash, staining with hematoxylin for 3 min, and a wash with water. Slides were visualized using a microscope (BX51, Olympus) equipped with a digital camera (DP70, Olympus).

For Nile red staining in intestinal epithelial cell-specific *Vmp1*-deficient mice fed *ad libitum*, frozen tissues were embedded and cryostat sectioned. Sections were washed three times with PBS and then stained with Nile red (1:1000, N1142, Thermo Fisher Scientific) for 15 min at room temperature. Coverslips were mounted with DAPI and examined under a confocal microscope (LSM 880 Meta plus Zeiss Axiovert zoom, Zeiss).

Alcian blue staining {#s4-9}
--------------------

Whole-mount Alcian blue staining to visualize the cartilage was performed according to the previous methods ([@bib61]). In brief, zebrafish larvae were maintained in 0.2 mM PTU from one dpf, fixed with 4% PFA overnight at 4°C, dehydrated with 50% ethanol for 10 min, stained with acid-free stain solution (0.02% Alcian blue (A5268, Sigma-Aldrich), 60 mM MgCl~2~, 70% ethanol) at room temperature overnight, cleared with 50% glycerol and 0.25% KOH at room temperature for 2 hr, dipped into 50% glycerol and 0.1% KOH, and viewed and photographed with a stereoscopic microscope (SZX10, Olympus).

Immunocytochemistry {#s4-10}
-------------------

Cells grown on coverslips (S2441, Matsunami) were washed with PBS and fixed with 4% PFA for 15 min at room temperature. Fixed cells were permeabilized with 0.1% Triton X-100 (35501--15, Nacalai Tesque) in PBS for 5 min and blocked with 3% BSA in PBS and incubated with specific antibodies for 1 hr. After washing with PBS, cells were incubated with Alexa Fluor 488- or 647-conjugated secondary antibodies for 1 hr. The coverslips were viewed using a confocal laser microscope (FV1000 IX81, Olympus) with a 100 × oil immersion objective lens (Olympus) and captured with FluoView software (Olympus). For the final output, the images were processed using Photoshop CS6 (Adobe). ImageJ software was used for quantification of the number and total pixel area of lipid-containing structures and the number of APOB- or ADRP-positive neutral lipid particles.

Electron microscopy {#s4-11}
-------------------

Zebrafish larvae were dissected at the abdomen under anesthesia with 0.03% tricaine, and fixed with 2% glutaraldehyde and 2% PFA in 0.1 M sodium cacodylate buffer (0.1% calcium chloride) overnight. For HepG2 cells, cells were cultured on a poly-L-lysine coated cell tight C-2 cell disk (MS-0113K, Sumitomo Bakelite) and fixed in 2.5% glutaraldehyde (G015, TAAB) in 0.1 M phosphate buffer (pH 7.4) for 2 hr. Tissues and cells were then post-fixed with 1.0% osmium tetroxide in 0.1 M phosphate buffer for 2 hr, dehydrated, and embedded in Epon 812 according to a standard procedure. Ultrathin sections were stained with uranyl acetate and lead citrate and observed using an H-7100 electron microscope (Hitachi).

Immunoblotting {#s4-12}
--------------

Zebrafish embryos or HepG2 cells were lysed with lysis buffer (50 mM Tris-HCl \[pH 7.5\], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM phenylmethanesulfonyl fluoride, and complete EDTA-free protease inhibitor cocktail \[19543200, Roche\]). After centrifugation at 15,000 × *g* for 20 min, the supernatants were collected, and the protein concentrations were adjusted using the bicinchoninic acid method (23228, Thermo Fisher Scientific). The lysates were solubilized with immunoblot sample buffer (46.7 mM Tris-HCl \[pH 6.8\], 5% glycerol, 1.67% sodium dodecyl sulfate \[SDS\], 1.55% dithiothreitol, and 0.003% bromophenol blue). The immunoblot samples were separated by SDS-polyacrylamide gel electrophoresis, transferred to an Immobilon-P polyvinylidene difluoride membrane (IPVH00010, Millipore), and blotted with primary and secondary antibodies. Each protein signal was detected with Super-Signal West Pico Chemiluminescent substrate (1856136, Thermo Fisher Scientific) or Immobilon Western Chemiluminescent HRP substrate (WBKLS0500, Millipore). Signal intensities were captured using FUSION SOLO7S (Vilber-Lourmat). The images were processed using Photoshop CS6 (Adobe).

Lipoprotein secretion assay {#s4-13}
---------------------------

HepG2 cells were treated with siRNA twice as described above and cultured in serum-free DMEM supplemented with 200 nM oleic acids-BSA for 24 hr in 12-well plates. The cells were washed with PBS and re-cultured in serum-free DMEM before analysis. The culture medium was centrifuged at 5000 x *g* for 3 min to remove any cells or cellular debris. The culture medium was then precipitated with 10% trichloroacetic acid (TCA), and the pellets were washed with ice-cold acetone twice and dissolved in immunoblot sample buffer. The cells were washed with PBS and lysed as described above. Samples (approximately 7% or 14% vol of total precipitated media or cell lysates, respectively) were subjected to immunoblot analysis. ImageJ software was used for densitometric quantification.

For chromatography analysis, siRNA-treated HepG2 cells (approximately 1.5 × 10^6^ cells) were cultured in 0.1% BSA containing DMEM with or without oleic acids-BSA for 48 hr before analysis. Lipoproteins in culture medium were analyzed using the gel permeation high performance liquid chromatography (Skylight Biotech Inc) system as previously described ([@bib42]). Briefly, lipoproteins in culture medium were separated with tandemly connected Skylight PakLP1-AA gel permeation columns (Skylight Biotech Inc; 300 mm × 4.6 mm I.D.). The column effluent was then equally split into two lines by a micro splitter, and each effluent was allowed to react at 37°C with the cholesterol and triglyceride reagents. Absorbance at 550 nm was continuously monitored after each enzymatic reaction in two reactor coils (PTFE; 25 m × 0.18 mm I.D.).

Triglyceride and cholesterol quantification {#s4-14}
-------------------------------------------

Six pairs of 18-month-old *Vmp1^flox/+^*;Villin-*Cre* mice and *Vmp1^flox/flox^*;Villin-*Cre* mice fed *ad libitum* were examined. Blood was allowed to stand for 2 hr and centrifuged at 1600 *g* for 15 min for collecting the serum. Serum samples were then measured by OLYMPUS AU480 automatic biochemical analyzer.

HepG2 cells were treated with siRNA twice as described above. HepG2 cells (approximately 1 × 10^5^ cells) were cultured in serum-free medium for 24 hr before analysis. For total lipid extraction from culture medium, the Bligh and Dyer method was performed. Both extra- and intra-cellular cholesterol and triglyceride levels were measured using quantitation kits (K603-100 and K622-100, respectively, Biovision Inc) according to the manufacturer's protocols.

Measurement of proteasome activity {#s4-15}
----------------------------------

Proteasomal activity was measured with the Proteasome-Glo kit (G8660, Promega). HepG2 cells were treated with siRNA twice as described above and plated equally (approximately 1 × 10^4^ cells per well) in 96-well white-walled plates. The cells were cultured with or without 5 μM lactacystin for 2 hr before measurement. Proteasome-Glo Cell-Based Reagent was prepared as per manufacturer's protocol and an equal volume was added to each well. The plate was mixed for 2 min using TAITEC E-36 micromixer and then incubated at room temperature for 10 min. Luminescence was measured by a microplate leader EnSpire (2300--00J, PerkinElmer).

Quantitative real-time PCR {#s4-16}
--------------------------

Total RNA was extracted from HepG2 cells using ISOGEN (319--90211, Nippon Gene) and reverse-transcribed using ReverTraAce (FSQ-201, TOYOBO) according to the manufacturer's instructions. PCR was performed by a Thermal Cycler Dice TP800 (TaKaRa Bio Inc) in triplicate using TB Green Premix Ex Taq II (RR820, TaKaRa Bio Inc). The expression level of *FITM2* was normalized to that of *ACTB*. Primers used are listed as follows: *FITM2*, 5′-AAAGGAACACCAGAGCAAGC-3′ and 5′-CCTCATGCAGCACAGACATC-3′; *ACTB*, 5′-ATTGCCGACAGGATGCAGAA-3′ and 5′-ACATCTGCTGGAAGGTGGACAG-3′.

Statistical analysis {#s4-17}
--------------------

Student *t*-test or Mann-Whitney U-test were performed to compare two groups. All data are presented as the mean ± standard error of the mean unless otherwise stated. Statistical analysis was performed using R software (R Core Team) or GraphPad Prism seven software (GraphPad software).
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Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing---review and editing, Assisted with electron microscopy studies.

Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing---review and editing, Carried out HPLC analysis of lipoproteins in culture medium.

Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Project administration, Writing---review and editing, Carried out experiments using intestinal epithelial cell-specific Vmp1-deficient mice.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing---original draft, Project administration, Writing---review and editing.

Animal experimentation: All animal experiments were approved by the Institutional Animal Care and Use Committee of the University of Tokyo (Medical-P17-084) and the Institutional Committee of the Institute of Biophysics, Chinese Academy of Sciences (SYXK2016-35).
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Data availability {#s7}
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All data generated or analysed during this study are included in the manuscript files. Source data files have been provided for Figures (1, 3, 4, 5, and 6), Figure 4---figure supplement 1, Figure 6---figure supplement 1, and Figure 6---figure supplement 2.

10.7554/eLife.48834.024

Decision letter

Pfeffer

Suzanne R

Reviewing Editor

Stanford University School of Medicine

United States

Pfeffer

Suzanne R

Reviewer

Stanford University School of Medicine

United States

Prinz

William A

Reviewer

National Institutes of Health

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"VMP1 is essential for release of lipoproteins from the endoplasmic reticulum membrane\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Suzanne Pfeffer as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: M. Mahmood Hussain (Reviewer \#3).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

This study addresses the role of the ER protein VMP1 in lipoprotein biogenesis. The first half of demonstrates that VMP1 deficiency causes embryonic lethality and the accumulation of neutral lipids in intestinal epithelial cells and hepatocytes of zebrafish and mice. The reviewers all agreed that this part of the study is well done and convincing. However, while the idea that VMP1 mediates lipoprotein release from the ER is consistent with the results, more work would be necessary to make a convincing case, likely requiring more than a few months.

One reviewer noted that the Zhang group has published compelling evidence that VMP1 regulates the ER calcium channel ATP2A/SERCA (Zhao and Zhang, Autophagy, 2018; Zhao et al., 2017) and disrupting ER calcium homoeostasis might indirectly affect lipoprotein biogenesis. In addition, the aberrant lipid droplet structures found in HepG2 cells depleted of VMP1 have been seen when the cells are treated with proteasome inhibitors, which indicates that they do not only form when lipoprotein biogenesis is directly impacted. Therefore, the reviewers felt it would be important to add data to show that the role is not indirect. This could be addressed by more broadly assessing ER function, ER stress, and lipid metabolism after VMP1 knockdown. It would also be good to know whether inducing ER stress by other mechanism causes similar lipid droplet structures to form in cells or whether the abnormal LD formation is specific to depletion of VMP1 or other proteins involved in lipoprotein biogenesis like MTTP. Another good way to tell whether VMP1 depletion specifically affects lipoprotein biogenesis would be to measure the initial rate of APOB secretion and measure secretion rates for control proteins like APOA-I or albumin. A paper addressing these issues could surely be re-evaluated as a new submission in the future, but we must decline the manuscript at this stage since significant additional work would be required.

*Reviewer \#1:*

This is a clear and well written paper that reports that VMP1 participates in lipoprotein biogenesis in the ER of zebrafish and mouse liver, intestine and visceral endoderm. In HepG2 cells, the authors see decreased secretion of triglycerides and cholesterol and a decrease in the lipoprotein marker, APOB. One experiment will add support to the conclusion that VMP1 acts early in the ER to drive release of nascent lipoprotein from the ER membrane and subsequent secretion: the authors should test the relative initial rate of APOB secretion from HepG2 cells ± VMP1. A 24 hour collection is more complicated by the altered regulation of APOBprotein seen in these cells (more rapid turnover) but the absolute rate of secretion can be monitored by 1, 2 and 4 hour time points for example and will provide a better metric of how important this protein is for lipoprotein secretion itself. This straightforward experiment will add much to the significance of this interesting story that should otherwise be published without delay in *eLife*.

Increased LC3-II is referred to as \"defective autophagy\" but perhaps it reflects increased autophagic flux?

*Reviewer \#2:*

This study addresses the role of the ER protein VMP1 in lipoprotein biogenesis. The first half of demonstrates that VMP1 deficiency causes embryonic lethality and the accumulation of neutral lipids in intestinal epithelial cells and hepatocytes of zebrafish and mice. The part of the study is well done and convincing. The second half argues that VMP1 facilitates release of lipoproteins from the ER membrane into the lumen of the ER. However, the study does not make a convincing case that VMP1 directly affects lipoprotein biogenesis or even that there is a defect in lipoprotein release into the ER lumen. Since very little is known about this process, it is not clear whether the APOB-/ADRP-positive lipid droplet structures are stalled intermediates in lipoprotein biogenesis or are off-pathway products, caused by factors such as changes in lipid metabolism or defects in lipid droplet emergence into the cytoplasm. In Ohsaki et al. (2008), the Fujimoto group showed that adding proteosome inhibitors to Huh7 cells (and they say HepG2 cells) induces formation of similar structures that are positive for both APOB and ADRP. Indeed, they see these structures even in about 10% of untreated cells. It seems possible that removing VMP1 from cells could cause ER stress or change lipid metabolism and similarly indirectly cause the formation of APOB-/ADRP-positive structures.

*Reviewer \#3:*

The investigators have generated VMP1 deficient zebrafish and mice and observed that this deficiency results in embryonic lethality. Using confocal microscopy they showed that APOB accumulates in cells. The major conclusion of the paper is that VMP1 is involved in desorption of LD from ER membrane. This conclusion is based on EM pictures presented in Figure 7. Investigators observed bulging of ER membrane in siVMP1 treated HepG2 cells. This suggests that some LD/lipoproteins assimilate in the ER membrane. Hence, they conclude that VMP1 helps in the dissociation of lipoproteins from the ER membrane. This is a novel finding of the paper and a novel function for *Vmp1*.

Plasma lipid and lipoprotein profile and lipid absorption studies in intestine-specific VMP1 KO mice would be required to ascertain the physiological importance of this protein in lipid absorption and lipoprotein assembly. Embryonic lethality can be attributed to VMP1\'s role in autophagy.

The paper provides convincing evidence that deficiency of VMP1 reduces APOB secretion in HepG2 cells. However, controls for the specificity are needed, such as secretion of APOA-I or albumin.

How does VMP1 help in the release of lipoproteins from the ER membrane? Does VMP1 interact with APOB? Does it interact with MTP? What happens to MTP in the absence of VMP1?

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration. The authors were asked to provide a plan for revisions before the editors issued a final decision. The authors' plan for revisions was approved and the authors made a formal revised submission.\]

Thank you for sending your article entitled \"VMP1 is essential for release of lipoproteins from the endoplasmic reticulum membrane\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, including Suzanne Pfeffer as the Reviewing Editor, and the evaluation is being overseen by Vivek Malhotra as the Senior Editor.

Given the list of comments, the editors and reviewers invite you to respond with an action plan and timetable for the completion of the additional work. We plan to share your responses with the reviewers and then issue a binding recommendation.

Reviewer 1\'s concerns are the most important:

\"I am still not convinced that VMP1 knockdown reduces the rate or extent of VLDL secretion from HepG2 cells. The evidence is inconsistent. Figure 4C, D suggests that there is a profound defect but is hard to reconcile with the data in Figure 4A, B and E, which suggest little change. In Figure 4E, the amount of APO proteins secreted after VMP knockdown is normalized to controls but it seems more appropriate to normalize it to the amount of APO remaining in the cells. When expressed in this way, there does not seem to be any decrease in the relative amount or rate of secretion of any of the APO proteins. How can this be reconciled with the evidence in Figure 4C, D?\"

Reviewer 3 felt that the conclusions went beyond the actual data and need to be toned down and clarified (see below); they wrote, \"The data indicate that VMP1 is not \"essential\" for APOB-lipoprotein assembly. If it was essential then we would have seen a more robust phenotype. It may play a role in lipoprotein secretion. But it is not a specific role. It probably plays a general role in secretion. This is based on the observation that there is reduction in APOB, APOA-I and APOE. This is not a new finding. The authors should be realistic in interpretation of their data.\"

*Reviewer \#1:*

The authors have tried to respond with care to each of the reviewer comments. In looking at the rate of release of APOB and APOE, they find APOB levels decrease but a clear decrease for APOE. The legend does not explain how the gels were loaded and needs to be clarified. Also, it would be clearer for the reader if the authors graphed percent of total apolipoprotein in medium on a graph with time as a linear function.

*Reviewer \#3:*

-- To prove definitely that VMP1 is essential for release of lipoproteins from the ER membranes, authors must follow APOB along with lipids. They should demonstrate that in the absence of VMP1, APOB remains in the ER membrane and is not present in the ER lumen. Thus, distribution of APOB and other control proteins in ER lumen and ER membrane must be studied. \[Is there a way for you to account for APOB in support of your conclusions?\]

-- In absence of APOB-lipoprotein assembly, secretion of APOA-I is largely unaffected. Thus, significant decrease in APOA-I secretion in these studies suggests that VMP1 may have a generalized effect on secretion of soluble proteins as cited in the third paragraph of the Introduction. Thus, the argument that VMP1 is specific for APOB-lipoproteins is weak. APOA-I is secreted independent of APOB-lipoproteins. Its secretion does not require removal from ER membrane.

-- Figure 5A: Is Sec61 surrounding the lipid droplet? It looks like LDs are in the lumen of ER. This suggests that they have been released from the ER membrane.

-- EM is required to show that VMP1 deficiency leads to the accumulation of LDs and APOB (immune-gold) in the ER membrane if the hypothesis is that VMP1 is critical for the release of lipoprotein from the ER membrane. \[Without such EM, can the conclusions be softened?\]

-- Need separation of ER lumen and membrane and distribution of lipids and APOB in these fractions \[if you want to conclude that the protein actually releases lipoprotein from ER membrane\].

-- It is likely that primordial lipoproteins are formed and they are in the ER lumen. VMP1 deficiency may interfere with their further transport to Golgi.

-- ADRP^+^ and APOB^+^ lipid droplets may be cytosolic droplets that contain APOB and may be unique to VMP1 deficiency.

-- This paper suggest that VMP1 is essential for the release of lipoproteins from the ER membrane, but the intestine-specific ablation phenotype on plasma is under whelming. Therefore, it is possible that VMP1 may play a role in lipoprotein secretion but it is not essential. Further, VMP1 deficiency appears to affect all apolipoprotein secretion. The authors are trying to over interpret their results. They should compare the phenotype in mice that are deficient in APOB and MTP; the two proteins known to be essential for B-lipoprotein assembly and secretion.

-- It is unclear why LDL and HDL are decreased. How did they measure LDL and HDL? Why cholesterol decreased but no change in triglyceride? This phenotype does not support the idea that VMP1 is essential for APOB-lipoprotein assembly and secretion. Most likely VMP1 is involved in general secretory pathway. Its deficiency slows down secretion of APOB. Similar thing is happening for APOA-I and APOE. Thus, there is little specificity to this process.

-- VMP1 also affects SERCA. Can the phenotype be explained by alterations in calcium pump in the ER?

-- Was blood collected from fasted mice?

-- Figure 3: Why there is a significant decrease in HDL? If VMP1 plays a role in APOB-lipoprotein assembly then it should not affect HDL levels. These data demand fat absorption studies in these mice to see if intestinal deficiency of VMP1 really has any significant defect in lipid absorption.

10.7554/eLife.48834.025

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> This study addresses the role of the ER protein VMP1 in lipoprotein biogenesis. The first half of demonstrates that VMP1 deficiency causes embryonic lethality and the accumulation of neutral lipids in intestinal epithelial cells and hepatocytes of zebrafish and mice. The reviewers all agreed that this part of the study is well done and convincing. However, while the idea that VMP1 mediates lipoprotein release from the ER is consistent with the results, more work would be necessary to make a convincing case, likely requiring more than a few months.
>
> One reviewer noted that the Zhang group has published compelling evidence that VMP1 regulates the ER calcium channel ATP2A/SERCA (Zhao and Zhang, Autophagy, 2018; Zhao et al., 2017) and disrupting ER calcium homoeostasis might indirectly affect lipoprotein biogenesis. In addition, the aberrant lipid droplet structures found in HepG2 cells depleted of VMP1 have been seen when the cells are treated with proteasome inhibitors, which indicates that they do not only form when lipoprotein biogenesis is directly impacted. Therefore, the reviewers felt it would be important to add data to show that the role is not indirect. This could be addressed by more broadly assessing ER function, ER stress, and lipid metabolism after VMP1 knockdown.

We found no changes in the proteasome activity, ER stress, and the MTTP protein level in VMP1-depleted HepG2 cells (Figure 6---figure supplement 1A-C). These results suggest that the function of the ER is not affected broadly.

> It would also be good to know whether inducing ER stress by other mechanism causes similar lipid droplet structures to form in cells or whether the abnormal LD formation is specific to depletion of VMP1 or other proteins involved in lipoprotein biogenesis like MTTP.

Crescent-shaped accumulations of APOB and ADRP around neutral lipids were not observed in HepG2 cells by treatment with proteasome inhibitors, ER stress inducers, or an MTTP inhibitor (Figure 6---figure supplement 2A-C) or by depletion of FITM2, a factor required for budding of lipid droplets from the ER to the cytosol (Figure 6---figure supplement 2D, E). Thus, as far as we have tested, the observed lipoprotein phenotype is rather specific to depletion of VMP1.

> Another good way to tell whether VMP1 depletion specifically affects lipoprotein biogenesis would be to measure the initial rate of APOB secretion and measure secretion rates for control proteins like APOA-I or albumin.

We now show defects in secretion of APOB, APOE, and APOA-I, but not albumin, in VMP1-depleted HepG2 cells at early time points (Figure 4E).

Other major experimental data that we have added are:

\- The levels of serum cholesterols and lipoproteins such as HDL decreased in intestinal epithelial cell-specific *Vmp1* KO mice (Figure 3G).

\- Lipid lens structures were not detected in the ER membrane in wild-type zebrafish and HepG2 cells (Figure 7A-C).

> Reviewer \#1:
>
> This is a clear and well written paper that reports that VMP1 participates in lipoprotein biogenesis in the ER of zebrafish and mouse liver, intestine and visceral endoderm. In HepG2 cells, the authors see decreased secretion of triglycerides and cholesterol and a decrease in the lipoprotein marker, APOB. One experiment will add support to the conclusion that VMP1 acts early in the ER to drive release of nascent lipoprotein from the ER membrane and subsequent secretion: the authors should test the relative initial rate of APOB secretion from HepG2 cells ± VMP1. A 24 hour collection is more complicated by the altered regulation of APOB protein seen in these cells (more rapid turnover) but the absolute rate of secretion can be monitored by 1, 2 and 4 hour time points for example and will provide a better metric of how important this protein is for lipoprotein secretion itself. This straightforward experiment will add much to the significance of this interesting story that should otherwise be published without delay in eLife.

We would like to thank the reviewer for this suggestion. As recommended, we have performed immunoblotting of APOB at 0, 1, 2, 4, and 24 h time points following 24-h oleic acid treatment, and found that the secretion of APOB was impaired in VMP1-depleted HepG2 cells from early time points. We have also found that secretion of APOE and APOA-I, which associate with lipoproteins in the ER in HepG2 cells (Chisholm et al., 2002, J Lipid Res; Fazio and Yao, 1995, Arterioscler Thromb Vasc Biol; Sundaram and Yao, 2010), was significantly impaired at early time points in VMP1-depleted HepG2 cells. Secretion of albumin, which is transported from the ER to Golgi separately from lipoproteins (Tiwari and Siddiqui, 2012), was slightly but not significantly impaired in VMP1-silenced HepG2 cells especially at early time points when secretion of apolipoproteins was significantly suppressed. Thus, a defect in secretion in VMP1-deficient cells is not general, but rather specific to lipoproteins. These results and discussion have been included in new Figure 4E and the text in the revised manuscript.

> Increased LC3-II is referred to as \"defective autophagy\" but perhaps it reflects increased autophagic flux?

If autophagic flux is blocked at a step downstream of LC3 lipidation, LC3-II should accumulate because of reduced turnover. This is the case in VMP1-depleted cells. In fact, recent studies using Vmp1-deficient HEK293T, HeLa, or MEF cells demonstrated that autophagic flux is completely suppressed in Vmp1-deficient cells that accumulate LC3-II (Itakura and Mizushima, 2010; Morita et al. 2018; Shoemaker et al., 2019; Zhao et al., 2017). We have included these references in the revised manuscript.

> Reviewer \#2:
>
> This study addresses the role of the ER protein VMP1 in lipoprotein biogenesis. The first half of demonstrates that VMP1 deficiency causes embryonic lethality and the accumulation of neutral lipids in intestinal epithelial cells and hepatocytes of zebrafish and mice. The part of the study is well done and convincing. The second half argues that VMP1 facilitates release of lipoproteins from the ER membrane into the lumen of the ER. However, the study does not make a convincing case that VMP1 directly affects lipoprotein biogenesis or even that there is a defect in lipoprotein release into the ER lumen. Since very little is known about this process, it is not clear whether the APOB-/ADRP-positive lipid droplet structures are stalled intermediates in lipoprotein biogenesis or are off-pathway products, caused by factors such as changes in lipid metabolism or defects in lipid droplet emergence into the cytoplasm. In Ohsaki et al. (2008), the Fujimoto group showed that adding proteosome inhibitors to Huh7 cells (and they say HepG2 cells) induces formation of similar structures that are positive for both APOB and ADRP. Indeed, they see these structures even in about 10% of untreated cells. It seems possible that removing VMP1 from cells could cause ER stress or change lipid metabolism and similarly indirectly cause the formation of APOB-/ADRP-positive structures.

We would like to thank the reviewer for valuable suggestions. As this reviewer mentions, very little is known about the process of lipoprotein biogenesis, particularly at the step of releasing into the ER lumen. We understand that it would be ideal to prove that VMP1 directly regulates this process, but this is difficult using currently available information. Given this situation, we believe that providing the first evidence that the ER protein VMP1 is required for the step is important and informative for the field. Nevertheless, we have tried to rule out secondary possibilities as much as possible as following.

To exclude the possibility that crescent-shaped accumulations of APOB and ADRP are secondarily induced by proteasome inhibition, we have evaluated the activity of proteasome and found that proteasome activity was not suppressed in VMP1-depleted HepG2 cells. Also, as opposed to the previous report by Fujimoto's group (Ohsaki et al., 2008), we hardly observed the crescent-shaped accumulations of APOB and ADRP in wildtype HepG2 cells irrespective of treatment with proteasome inhibitors (MG132 and lactacystin) (0% of randomly selected cells (n ≥ 39) with or without proteasome inhibitors). Furthermore, VMP1-depleted HepG2 cells did not demonstrate ER stress and reduced MTTP protein level, which can induce APOB proteolysis, and that treatment of wild-type HepG2 cells with ER stress inducers (tunicamycin and thapsigargin) or an MTTP inhibitor (CP346086) did not induce the crescent-shaped accumulations of APOB and ADRP. These results suggest that the crescent-shaped accumulations of APOB and ADRP is independent of proteasome inhibition, ER stress, and MTTP inhibition in HepG2 cells. These data have been included in the revised manuscript in new Figure 6---figure supplement 1A-C and Figure 6---figure supplement 2A-C.

To determine whether the crescent-shaped accumulations of APOB and ADRP are induced as a result of a defect in lipid droplet emergence into the cytosol, we have depleted FITM2 that is required for budding of lipid droplets (Kadereit et al., 2008; Choudhary et al., 2015) but not for lipoprotein secretion (Goh et al., 2015). Deletion of FITM2 in HepG2 cells caused a reduction of the total volume of lipid droplets as reported in FITM2-depleted adipocytes, zebrafish, and *C. elegans* (Kadereit et al., 2008; Choudhary et al., 2015). However, the crescent-shaped accumulations of APOB and ADRP were not observed in FITM2-depleted HepG2 cells. Thus, it is unlikely that defective budding of lipid droplets from the ER membrane causes the impairment of lipoprotein budding in VMP1-depleted cells. These data have been included in the revised manuscript in new Figure 6---figure supplement 2D, E.

We agree with the comment that crescent-shaped accumulations of APOB and ADRP may be induced as a result of an alteration of lipid metabolism. Indeed, recent studies have suggested that release of lipoproteins and lipid droplets from the ER membrane is regulated by lipid metabolism such as phospholipid remodeling (Ben M\'barek et al., 2017; Wang and Tontonoz, 2019), suggesting the possible role of VMP1 in lipid metabolism. More extensive investigation, including lipidomic analyses of VMP1-depleted cells and mechanistic in vitro assays, would be required to examine this hypothesis, which we believe would be a separate complete work. We have discussed this point in the second paragraph of Discussion.

> Reviewer \#3:
>
> The investigators have generated VMP1 deficient zebrafish and mice and observed that this deficiency results in embryonic lethality. Using confocal microscopy they showed that APOB accumulates in cells. The major conclusion of the paper is that VMP1 is involved in desorption of LD from ER membrane. This conclusion is based on EM pictures presented in Figure 7. Investigators observed bulging of ER membrane in siVMP1 treated HepG2 cells. This suggests that some LD/lipoproteins assimilate in the ER membrane. Hence, they conclude that VMP1 helps in the dissociation of lipoproteins from the ER membrane. This is a novel finding of the paper and a novel function for Vmp1.
>
> Plasma lipid and lipoprotein profile and lipid absorption studies in intestine-specific VMP1 KO mice would be required to ascertain the physiological importance of this protein in lipid absorption and lipoprotein assembly.

We would like to thank the reviewer for valuable suggestions. As recommended, we quantified the amount of serum triglyceride, cholesterol, LDL, and HDL in intestinal epithelial cell-specific *Vmp1* KO mice, and found that levels of cholesterol and HDL were significantly reduced in *Vmp1* KO mice. In contrast, the level of serum triglyceride did not decrease. We speculate that this could be due to a possible compensatory mechanism. We have included the data in new Figure 3G and discussed this point in the last paragraph of Discussion.

> Embryonic lethality can be attributed to VMP1\'s role in autophagy.

As we have already discussed in the original version, the timing of lethality of *Vmp1* KO mice (around 8.5 dpc) is earlier than that of mice deficient for other core autophagy-related genes such as *Rb1cc1* (around 16 dpc)*, Atg13* (around 17 dpc), and *Atg5* (around 0.5 day after birth) (Kuma et al., 2017; Mizushima and Levine, 2010). Thus, we think that the early embryonic lethality of *Vmp1* KO mice is due to defects in autophagy-independent pathways.

> The paper provides convincing evidence that deficiency of VMP1 reduces APOB secretion in HepG2 cells. However, controls for the specificity are needed, such as secretion of APOA-I or albumin.

We thank the reviewer for pointing this out. As recommended, we have performed immunoblotting of APOB, APOE, APOA-I, and albumin at 0, 1, 2, 4, and 24 h time points following 24-h oleic acid treatment, and found that the secretion of not only APOB but also APOE and APOA-I was significantly impaired at early time points in VMP1-depleted HepG2 cells. Secretion of albumin, which is transported from the ER to Golgi separately from lipoproteins (Tiwari and Siddiqui, 2012), was slightly but not significantly impaired in VMP1-silenced HepG2 cells especially at early time points. Thus, a defect in secretion in VMP1-deficient cells is not general, but rather specific to lipoproteins. These results and discussion have been included in new Figure 4E and the text in the revised manuscript.

> How does VMP1 help in the release of lipoproteins from the ER membrane? Does VMP1 interact with APOB? Does it interact with MTP? What happens to MTP in the absence of VMP1?

As suggested by the reviewer, we have performed immunoprecipitation assays and found that FLAG-VMP1 interacted with endogenous APOB, but not MTTP, in HepG2 cells ([Author response image 1](#respfig1){ref-type="fig"}). However, this interaction was weak and only detected when we used the detergent Triton X-100 (1%), but not dodecyl maltoside (1%)/cholesteryl hemisuccinate (0.2%). Thus, more extensive investigation would be required to prove this potential interaction and its physiological relevance, which we believe would be a separate complete work.

To investigate the effect of VMP1 deficiency on MTTP, we have performed immunoblotting of MTTP and found that there was no difference in the protein level of MTTP between wild-type and VMP1-depleted HepG2 cells. Also, crescent-shaped accumulations of APOB and ADRP were not observed in wild-type HepG2 cells after 24-h treatment with the MTTP inhibitor CP-346086. These results suggest that defective release of lipoproteins from the ER membrane in VMP1-depleted HepG2 cells is not caused by MTTP inhibition. These results have been included in new Figure 6---figure supplement 1C and Figure 6---figure supplement 2C in the revised manuscript.

![Interaction of VMP1 with APOB not MTTP is detected using the detergent 1% Triton-X100, but not dodecyl maltoside (1%)/cholesteryl hemisuccinate (0.2%).\
HepG2 cells were transfected with FLAG-VMP1 and lysed using lysis buffer containing 1% Triton-X100 (20 mM Tris-HCI, pH 8.0, 150 mM NaCl, 10% glycerol, 1% Triton-X100) or lysis buffer containing dodecyl maltoside (1%) and cholesteryl hemisuccinate (0.2%) (20 mM Tris-HCI, pH 8.0, 150 mM NaCl, 10% glycerol, 1% dodecyl maltoside \[DDM\], and 0.2% cholesteryl hemisuccinate \[CHS\]). Immunoprecipitation was performed using anti-FLAG M2 affinity gel. SDS-PAGE and immunoblotting was performed using indicated antibodies.](elife-48834-resp-fig1){#respfig1}

\[Editors\' note: the authors' plan for revisions was approved and the authors made a formal revised submission.\]

> Reviewer 1\'s concerns are the most important:
>
> \"I am still not convinced that VMP1 knockdown reduces the rate or extent of VLDL secretion from HepG2 cells. The evidence is inconsistent. Figure 4C, D suggests that there is a profound defect but is hard to reconcile with the data in Figure 4A, B and E, which suggest little change. In Figure 4E, the amount of APO proteins secreted after VMP knockdown is normalized to controls but it seems more appropriate to normalize it to the amount of APO remaining in the cells. When expressed in this way, there does not seem to be any decrease in the relative amount or rate of secretion of any of the APO proteins. How can this be reconciled with the evidence in Figure 4C, D?\"

According to the reviewer's suggestion, we re-evaluated lipoprotein secretion by calculating the ratio of the extracellular amount to intracellular amount of each protein (normalized to 0 h), and found that secretion of APOB and APOE, but not Albumin, was significantly reduced in VMP1-silenced cells (new Figure 4C). The secretion of APOA-I was only slightly reduced. These results suggest that a defect in secretion in VMP1-deficient cells is not general, but rather specific to lipoproteins (particularly APOB and APOE).

As we planned, we also performed a similar experiment in the presence of proteasome inhibitors to inhibit secondary degradation of intracellular apolipoproteins, but the results were not convincing probably because of cell death due to prolonged proteasome inhibition and, therefore, not included in the manuscript.

The inconsistency between the results in Figure 4A, B, E and 4C, D could be due to a difference in detection sensitivity of the methods used. Considering the fact that the defect in lipoprotein secretion was mild in epithelial cell-specific Vmp1 KO mice (Figure 3G), we think that the results in Figures 4A, B, E should correctly reflect the actual situation. Nevertheless, the HPLC data in Figures 4C, D still support our conclusion that there is a difference in the amount of secreted lipoproteins between control and VMP1-silenced cells. Thus, we have moved the HPLC data in original Figures 4C, D to new Figure 4---figure supplement 1A, B, and stated that different detection methods were used in new Figures 4A, B and new Figure 4---figure supplement 1A, B in the manuscript as follows; "Chromatographic analysis using different detection methods for neutral lipids also revealed significant reductions in lipoproteins".

> Reviewer 3 felt that the conclusions went beyond the actual data and need to be toned down and clarified (see below); they wrote, \"The data indicate that VMP1 is not \"essential\" for APOB-lipoprotein assembly. If it was essential then we would have seen a more robust phenotype. It may play a role in lipoprotein secretion. But it is not a specific role. It probably plays a general role in secretion. This is based on the observation that there is reduction in APOB, APOA-I and APOE. This is not a new finding. The Authors should be realistic in interpretation of their data.\"

We agree that the phenotypes of Vmp1-deficient animals are milder than those of APOB- or MTTP-deficient animals. Thus, we have changed the title to \"A critical role of VMP1 in lipoprotein secretion\" to better reflect our results that VMP1 is not absolutely essential. Also, we have replaced the word \"required\" with \"important\" throughout the manuscript.

We did not claim that the function of VMP1 is specific to APOB assembly/secretion. As aforementioned, we have re-evaluated secretion of lipoproteins and confirmed that a defect in secretion in VMP1-deficient cells is not general, but rather specific to lipoproteins (new Figure 4C). In addition, we found that APOE was also trapped in large lipid structures in VMP1-silenced HepG2 cells (new Figure 6E). In contrast, APOA-I was not trapped in these lipid structures (new Figure 6F), which is consistent with the results of the secretion assay that the secretion of APOA-I was not much affected. Thus, we suggest in the text that defective secretion of APOB and APOE (new Figure 4C) is at least partly caused by trapping in the lipid structures (subsection "VMP1 is important for the release of lipoproteins from the ER membrane", second paragraph).

We agree that VMP1 has a general role in secretion, as we mentioned in the previous version. It was shown in *Drosophila* S2 cells (Bard et al., 2006) and *Dictyostelium* (Calvo-Garrido et al., 2008). However, it is not shown in *Caenorhabditis elegans* or mammalian cells (Zhao et al., 2017). In *vmp1*-deficient zebrafish, formation of cartilage, which requires secretion of collagens, normally occurs and embryonic development was normal. Electron microscopy revealed the presence of lipid particles that are partially, but not completely, surrounded by ER membranes in VMP1-depleted cells (Figure 7), suggesting that neutral lipids were not completely released into the ER lumen. Furthermore, cells lacking factors required for budding from the ER to Golgi (e.g., TANGO1, TALI (Santos et al., 2016), cTAGE5 (Wang et al., 2016), or Surf4 (Saegusa et al., 2018)) did not show accumulation of similar large lipid-containing structures. Thus, these data suggest that, while VMP1 is important for general secretion in some cell types, the role of VMP1 in secretion is rather specific to lipoproteins in mammals and fish. However, as it is technically difficult to definitely demonstrate where each apolipoprotein and neutral lipids accumulate in the ER, we add the sentence "we do not exclude the possibility that VMP1 is also important at the step of ER-to-Golgi budding, which is not mutually exclusive".

> Reviewer \#1:
>
> The authors have tried to respond with care to each of the reviewer comments. In looking at the rate of release of APOB and APOE, they find APOB levels decrease but a clear decrease for APOE. The legend does not explain how the gels were loaded and needs to be clarified. Also, it would be clearer for the reader if the authors graphed percent of total apolipoprotein in medium on a graph with time as a linear function.

We have now shown the results on a graph with time as a linear function in Figure 4C and included the information about the methods in the legend and Materials and methods as follows; "The medium was concentrated by TCA precipitation. Samples (approximately 7% or 14% volume of total precipitated media or cell lysates, respectively) were subjected to immunoblot analysis".

> Reviewer \#3:
>
> -- To prove definitely that VMP1 is essential for release of lipoproteins from the ER membranes, authors must follow APOB along with lipids. They should demonstrate that in the absence of VMP1, APOB remains in the ER membrane and is not present in the ER lumen. Thus, distribution of APOB and other control proteins in ER lumen and ER membrane must be studied. \[Is there a way for you to account for APOB in support of your conclusions?\]

We agree with this comment. However, in VMP1-deficient cells, the space between the ER membrane and lipids is very narrow (please see Figure 7D). In this case, it is very difficult to definitely prove that APOB indeed remains within the ER membrane bilayers but not present in the ER lumen by currently available methods (e.g., biochemical and immunoelectron microscopy). In fact, Dr. Fujimoto's group previously showed the presence of APOB on similar structures (Ohsaki et al., 2008), but the data cannot tell whether APOB remains inside the membrane or in the lumen. We believe that our data showing that some of the lipid-containing structures are also positive for ADRP (please see Figure 6C, D) also suggest that these are not released into the lumen. We have mentioned this limitation in Discussion as follows; "However, as it is technically difficult to definitely demonstrate where each apolipoprotein and neutral lipids accumulate in the ER, we do not exclude the possibility that VMP1 is also important at the step of ER-to-Golgi budding, which is not mutually exclusive."

> -- In absence of APOB-lipoprotein assembly, secretion of APOA-I is largely unaffected. Thus, significant decrease in APOA-I secretion in these studies suggests that VMP1 may have a generalized effect on secretion of soluble proteins as cited in the third paragraph of the Introduction. Thus, the argument that VMP1 is specific for APOB-lipoproteins is weak. APOA-I is secreted independent of APOB-lipoproteins. Its secretion does not require removal from ER membrane.

As mentioned above, we did not claim that the function of VMP1 in lipoprotein secretion is specific to APOB. In the re-evaluation of the secretion of lipoproteins, we found that secretion of APOE was also affected in VMP1-silenced HepG2 cells (new Figure 4C). The secretion of APOA-I was also affected but only slightly. As mentioned above, we have discussed the possible role of VMP1 in the ER-to-Golgi pathway (Discussion, first paragraph).

> -- Figure 5A: Is Sec61 surrounding the lipid droplet? It looks like LDs are in the lumen of ER. This suggests that they have been released from the ER membrane.

We agree that some but not all of large lipid-containing structures appear to be almost completely surrounded by Sec61B. However, the Sec61B signal is not always uniform; a significant number of these structures have Sec61B-weak regions (arrows in [Author response image 2](#respfig2){ref-type="fig"}). Furthermore, APOB-weak or -negative regions are sometimes positive for ADRP (Figure 6C, D), suggesting that these are not released into the lumen. We have replaced the magnified images in Figure 5A with more representative ones and indicated Sec61B-weak regions.

![Immunohistochemistry of the liver from 6-dpf *vmp1^-/-^* zebrafish using anti-Sec61B antibody and LipidTOX Red.\
Arrows indicate the regions where the Sec61B signals were weak. Magnified pictures of Figure 5A.](elife-48834-resp-fig2){#respfig2}

> -- EM is required to show that VMP1 deficiency leads to the accumulation of LDs and APOB (immune-gold) in the ER membrane if the hypothesis is that VMP1 is critical for the release of lipoprotein from the ER membrane. \[Without such EM, can the conclusions be softened?\]
>
> -- Need separation of ER lumen and membrane and distribution of lipids and APOB in these fractions \[if you want to conclude that the protein actually releases lipoprotein from ER membrane\].

As aforementioned, it is difficult to prove that APOB is present on the ER membrane but not in the ER lumen by immunoelectron microscopy. It is also difficult to biochemically separate the ER membrane and ER lumen with intact localization of APOB. As mentioned above, we have discussed these limitations in the text (Discussion, first paragraph).

> -- It is likely that primordial lipoproteins are formed and they are in the ER lumen. VMP1 deficiency may interfere with their further transport to Golgi.

Although we cannot rule out this possibility, we think that it is less likely because most neutral lipids were not completely surrounded by the ER membrane (Figures 5A, B, and Figure 7).

> -- ADRP^+^ and APOB^+^ lipid droplets may be cytosolic droplets that contain APOB and may be unique to VMP1 deficiency.

Although we cannot rule out this possibility, we think that it is less likely. As the total number of ADRP-positive structures is significantly reduced (Figure 6C), the formation of cytosolic lipid droplets should also be defective in VMP1-depleted cells.

> -- This paper suggest that VMP1 is essential for the release of lipoproteins from the ER membrane, but the intestine-specific ablation phenotype on plasma is under whelming. Therefore, it is possible that VMP1 may play a role in lipoprotein secretion but it is not essential. Further, VMP1 deficiency appears to affect all apolipoprotein secretion. The authors are trying to over interpret their results. They should compare the phenotype in mice that are deficient in APOB and MTP; the two proteins known to be essential for B-lipoprotein assembly and secretion.

We agree that the phenotype of intestine-specific Vmp1 knockout mice is milder than that of intestine-specific Mttp knockout mice (Iqbal et al., 2013; Xie et al., 2006). We have added discussion regarding the difference in phenotype between these models as follows; "In contrast to intestinal epithelial cell-specific Mttp-deficient mice (Iqbal et al., 2013; Xie et al., 2006), intestinal epithelial cell-specific Vmp1-deficient mice showed milder phenotypes in lipoprotein secretion; the level of serum triglyceride did not decrease in intestinal epithelial cell-specific Vmp1-deficient mice (Figure 3G). Thus, although VMP1 is important, it is not absolutely essential for lipoprotein secretion." Also, we have changed the manuscript title to better reflect our results and replaced the word \"required\" with \"important\" throughout the manuscript.

> -- It is unclear why LDL and HDL are decreased. How did they measure LDL and HDL? Why cholesterol decreased but no change in triglyceride? This phenotype does not support the idea that VMP1 is essential for APOB-lipoprotein assembly and secretion. Most likely VMP1 is involved in general secretory pathway. Its deficiency slows down secretion of APOB. Similar thing is happening for APOA-I and APO**E**. Thus, there is little specificity to this process.

We have measured LDL and HDL in mice using an OLYMPUS AU480 automatic biochemical analyzer equipped with standard reagents that can selectively separate LDL or HDL from other lipoproteins and quantify the amount of LDL or HDL cholesterol, according to the manufacturer\'s explanation. We don't know the reason why levels of triglyceride were preserved in intestinal epithelial cell-specific *Vmp1*-deficient mice, but it is likely due to a possible compensatory mechanism, which will be investigated elsewhere in the future. As we discussed above, we think that VMP1 is not absolutely essential for lipoprotein secretion and is not specific to APOB.

> -- VMP1 also affects SERCA. Can the phenotype be explained by alterations in calcium pump in the ER?

We also thought this possibility, but ADRP^+^ and APOB^+^ crescent structures were not formed in cells treated with thapsigargin, a SERCA inhibitor (Figure 6---figure supplement 2B). Thus, the phenotypes by VMP1-deficiency cannot simply be explained by SERCA inhibition.

> -- Was blood collected from fasted mice?

As we have mentioned in the figure legend and Materials and methods in the original version, we used mice fed ad libitum.

> -- Figure 3: Why there is a significant decrease in HDL? If VMP1 plays a role in APOB-lipoprotein assembly then it should not affect HDL levels. These data demand fat absorption studies in these mice to see if intestinal deficiency of VMP1 really has any significant defect in lipid absorption.

We actually do not have any idea why HDL was reduced in *Vmp1*-deficient mice. Further analysis will be required to address this question using intestinal epithelial cell-specific *Vmp1*-deficient mice, which will take more than one year for us. We think that such detailed lipid analysis is beyond the scope of this first cell biological report.
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